Heart failure in diabetes: From an increased risk to a treatment target

Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there ha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Eberhard Standl
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	type 2 diabetes mellitus heart failure cardiovascular outcome trials dpp-4 inhibitors sglt-2 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/357945c2fd334a2ab4f8e387448d76be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:357945c2fd334a2ab4f8e387448d76be
record_format	dspace
spelling	oai:doaj.org-article:357945c2fd334a2ab4f8e387448d76be2021-11-14T09:00:22ZHeart failure in diabetes: From an increased risk to a treatment target2072-03512072-037810.14341/DM9846https://doaj.org/article/357945c2fd334a2ab4f8e387448d76be2018-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9846https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there has been an increasing concern regarding the cardiovascular (CV) safety profile of these agents. In view of this, FDA mandated the demonstration of cardiovascular risk-benefit profile of these agents through specifically designed CV outcome trials. Although we have several findings from these trials, none of them included HF as a primary endpoint indicating the need of trials focusing on HF. Here, we briefly discuss the results of the CV outcome trials in the context of HF.Eberhard StandlEndocrinology Research Centrearticletype 2 diabetes mellitusheart failurecardiovascular outcome trialsdpp-4 inhibitorssglt-2 inhibitorsglp-1 receptor agonistsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 5, Pp 399-403 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus heart failure cardiovascular outcome trials dpp-4 inhibitors sglt-2 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus heart failure cardiovascular outcome trials dpp-4 inhibitors sglt-2 inhibitors glp-1 receptor agonists Nutritional diseases. Deficiency diseases RC620-627 Eberhard Standl Heart failure in diabetes: From an increased risk to a treatment target
description	Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there has been an increasing concern regarding the cardiovascular (CV) safety profile of these agents. In view of this, FDA mandated the demonstration of cardiovascular risk-benefit profile of these agents through specifically designed CV outcome trials. Although we have several findings from these trials, none of them included HF as a primary endpoint indicating the need of trials focusing on HF. Here, we briefly discuss the results of the CV outcome trials in the context of HF.
format	article
author	Eberhard Standl
author_facet	Eberhard Standl
author_sort	Eberhard Standl
title	Heart failure in diabetes: From an increased risk to a treatment target
title_short	Heart failure in diabetes: From an increased risk to a treatment target
title_full	Heart failure in diabetes: From an increased risk to a treatment target
title_fullStr	Heart failure in diabetes: From an increased risk to a treatment target
title_full_unstemmed	Heart failure in diabetes: From an increased risk to a treatment target
title_sort	heart failure in diabetes: from an increased risk to a treatment target
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/357945c2fd334a2ab4f8e387448d76be
work_keys_str_mv	AT eberhardstandl heartfailureindiabetesfromanincreasedrisktoatreatmenttarget
_version_	1718429517798703104

Heart failure in diabetes: From an increased risk to a treatment target

Ejemplares similares